Emerging therapeutic targets for idiopathic pulmonary fibrosis: preclinical progress and therapeutic implications.

Yanagihara, Toyoshi; Scallan, Ciaran; Ask, Kjetil; Kolb, Martin R J

Yanagihara, Toyoshi; Scallan, Ciaran; Ask, Kjetil; Kolb, Martin R J.

Afiliação

Yanagihara T; Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Scallan C; Department of Respiratory Medicine, Hamanomachi Hospital, Fukuoka, Japan.
Ask K; Firestone Institute for Respiratory Health, Research Institute at St Joseph's Healthcare, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Kolb MRJ; Firestone Institute for Respiratory Health, Research Institute at St Joseph's Healthcare, Department of Medicine, McMaster University, Hamilton, ON, Canada.

Expert Opin Ther Targets ; 25(11): 939-948, 2021 11.

Article em En | MEDLINE | ID: mdl-34784834

Assuntos

Fibrose Pulmonar Idiopática; Biomarcadores; Progressão da Doença; Desenvolvimento de Medicamentos; Humanos; Fibrose Pulmonar Idiopática/tratamento farmacológico

Palavras-chave

IPF; biomarker; idiopathic pulmonary fibrosis; novel targets; therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrose Pulmonar Idiopática Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Expert Opin Ther Targets Assunto da revista: TERAPEUTICA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google